Efficacy for glycemic control : Clinical trials of semaglutide (SUSTAIN program) have demonstrated hemoglobin A1c reductions of 1.5-2.0% in patients with type 2 diabetes, with many patients achieving A1c levels below 7%
Therefore, Semaglutide doesnt directly affect the hormonal levels associated with the menstrual cycle, so it doesnt directly affect the menstrual cycle
Additionally, we have identified eight new adverse events (AE) which include ketosis, euglycemic diabetic ketoacidosis, pancreatic cancer, sixth cranial nerve palsy, hyperglycemic hyperosmolar nonketotic syndrome, elevated glycated hemoglobin, positional dizziness, and belching
At full therapeutic doses, roughly 40% of patients experience GI side effects severe enough to consider stopping
Where MIC Fits Now That GLP-1s Exist This is the question that has changed the category, and any guidance written before 2024 simply does not address it